Revenue: As of FY2025, the actual value is USD 7.425 M.

EPS: As of FY2025, the actual value is USD -1.607.

EBIT: As of FY2025, the actual value is USD -3.029 M.

Consolidated Financial Performance

Gross Profit

Total Gross Profit decreased from $1,289,521 in fiscal year 2024 to $1,085,217 in fiscal year 2025.

Operating Expenses

Total Operating Expenses decreased by 9% from - $4,935,696 in fiscal year 2024 to - $4,482,399 in fiscal year 2025. Sales and Marketing expenses decreased from - $2,030,684 in 2024 to - $1,736,331 in 2025. Research and Development expenses increased slightly from - $47,511 in 2024 to - $50,670 in 2025. General and Administrative expenses decreased from - $1,832,968 in 2024 to - $1,535,452 in 2025. Share-based Compensation increased from - $141,000 in 2024 to - $794,770 in 2025. Provision for Expected Credit Losses decreased from - $883,533 in 2024 to - $271,211 in 2025.

Loss from Operations

Total Loss from Operations increased by 88% from - $1,573,702 in fiscal year 2024 to - $2,965,065 in fiscal year 2025.

Finance Costs

Total Finance Costs decreased from - $21,146 in fiscal year 2024 to - $19,542 in fiscal year 2025.

Net Loss Attributable to Common Shareholders

Total Net Loss increased from - $1,598,342 in fiscal year 2024 to - $2,984,607 in fiscal year 2025.

Comprehensive Loss

Total Comprehensive Loss increased from - $1,476,048 in fiscal year 2024 to - $2,550,356 in fiscal year 2025.

Liquidity and Capital Resources

• Working Capital decreased from $5,479,146 at December 31, 2024, to $4,927,781 at December 31, 2025.
• Net Cash Used in Operating Activities was - $1,838,382 in 2025, compared to - $2,093,260 in 2024.
• Net Cash Generated from Investing Activities was $944,751 in 2025, compared to $418,202 in 2024.
• Net Cash Generated from Financing Activities was $298,841 in 2025, compared to $3,975 in 2024.
• Cash and Cash Equivalents, End of Financial Year, were $2,486,383 in 2025, compared to $2,886,966 in 2024.

Research and Development

Consolidated R&D Budget was $50,670 in 2025, compared to $47,511 in 2024.

Income Taxes

• Net Operating Loss (NOL) Carryforwards (USA) were $8,938,122 as of December 31, 2025.
• Net Operating Loss (NOL) Carryforwards (Malaysia) were $2,567,801 as of December 31, 2025.
• Valuation Allowance for Deferred Tax Assets increased by $2,203,533 in 2025 to $11,607,175.

Segmented Financial Performance

Provision for Genomic Screening Services (MRNA Scientific)

• Gross Profit increased from $8,753 in 2024 to $9,754 in 2025.
• Gross Margin Percentage decreased from 54.5% in 2024 to 51.1% in 2025.
• Other Income increased by 45.1% from $122,951 in 2024 to $178,452 in 2025.
• Operating Expenses increased from - $366,848 in 2024 to - $397,851 in 2025.
• Loss from Operations decreased from - $235,144 in 2024 to - $209,645 in 2025.
• Finance Costs increased from - $11,795 in 2024 to - $12,709 in 2025.
• Net Loss Attributable to Common Shareholders decreased from - $246,939 in 2024 to - $222,354 in 2025.
• Segment Assets decreased from $2,652,754 in 2024 to $2,281,947 in 2025.
• Addition to Non-Current Assets decreased significantly from $150,881 in 2024 to $1,382 in 2025.

Trading of Industrial Chemicals (Chemrex)

• Gross Profit decreased from $1,280,768 in 2024 to $1,075,463 in 2025.
• Gross Margin Percentage improved from 13.6% in 2024 to 14.6% in 2025.
• Other Income decreased by 87% from $1,949,522 in 2024 to $253,665 in 2025.
• Operating Expenses decreased from - $3,424,310 in 2024 to - $2,375,539 in 2025.
• Loss from Operations increased from - $194,020 in 2024 to - $1,046,411 in 2025.
• Finance Costs decreased from - $9,072 in 2024 to - $6,645 in 2025.
• Net Loss Attributable to Common Shareholders increased from - $206,586 in 2024 to - $1,053,056 in 2025.
• Segment Assets decreased from $6,788,302 in 2024 to $4,577,690 in 2025.
• Addition to Non-Current Assets decreased from $221,844 in 2024 to $35,589 in 2025.

Investment Holding

• Operating Expenses increased from - $1,144,538 in 2024 to - $1,709,009 in 2025.
• Loss from Operations increased from - $1,144,538 in 2024 to - $1,709,009 in 2025.
• Finance Costs decreased from - $279 in 2024 to - $188 in 2025.
• Net Loss Attributable to Common Shareholders increased from - $1,144,817 in 2024 to - $1,709,197 in 2025.
• Segment Assets increased from $992,792 in 2024 to $2,393,147 in 2025.
• Addition to Non-Current Assets remained $0 for both 2024 and 2025.

Outlook / Guidance

BioNexus Gene Lab Corp. plans to address internal control deficiencies and establish a group-level risk and compliance framework. The company expects to continue developing its VitaGuard™ Minimal Residual Disease (MRD) platform in Southeast Asia and expand into digital healthcare markets, including co-investment projects with the Malaysian government. Potential revenue acceleration is anticipated through strategic alliances, mergers, or acquisitions facilitated by its investment banking advisor.